Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience

被引：10

作者：

Memoli, Mara ^{[1
,2
]}

Paviglianiti, Annalisa ^{[1
]}

Malard, Florent ^{[1
,3
,4
]}

Battipaglia, Giorgia ^{[1
,4
]}

Brissot, Eolia ^{[1
,3
,4
]}

Mediavilla, Clemence ^{[1
,4
]}

Bianchessi, Antonio ^{[1
,5
]}

Banet, Anne ^{[1
]}

Van de Wyngaert, Zoe ^{[1
]}

Ledraa, Tounes ^{[1
]}

Belhocine, Ramdane ^{[1
]}

Sestili, Simona ^{[1
]}

Lapusan, Simona ^{[1
]}

Hirsch, Pierre ^{[3
,4
,6
]}

Favale, Fabrizia ^{[3
,4
,6
]}

Boussaroque, Agathe ^{[3
,4
,6
]}

Bonnin, Agnes ^{[1
]}

Vekhoff, Anne ^{[1
]}

Legrand, Ollivier ^{[1
,3
,4
]}

Mohty, Mohamad ^{[1
,3
,4
]}

Dulery, Remy ^{[1
,3
,4
]}

机构：

[1] St Antoine Hosp, AP HP, Dept Hematol & Cellular Therapy, 184 Rue Faubourg St Antoine, F-75012 Paris, France

[2] Univ Naples Federico II, Hematol & Hematopoiet Stem Cell Transplant Ctr, Dept Med & Surg, Naples, Italy

[3] INSERM, UMRs 938, Paris, France

[4] Sorbonne Univ, Hop St Antoine, AP HP, Paris, France

[5] Univ Pavia, Dept Mol Med, Pavia, Italy

[6] Hop St Antoine, AP HP, Serv Hematol Biol, Paris, France

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 02期

关键词：

Thiotepa; busulfan; fludarabine; HSCT; TBF; myelofibrosis; STEM-CELL TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; LEUKEMIA WORKING PARTY; HAPLOIDENTICAL TRANSPLANTATION; EUROPEAN-SOCIETY; RISK-FACTORS; MARROW; SPLENECTOMY; RUXOLITINIB; MANAGEMENT;

D O I：

10.1080/10428194.2020.1827246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10-42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23-65) at 3 years. The median follow-up period was 39 (range 14-60) months. Overall survival was 69% (95% CI, 50-83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.

引用

收藏

页码：419 / 427

页数：9

相关论文

共 50 条

[31] Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients [J].

Jiang, Jie-ling ;

Gao, Wen-hui ;

Wang, Li-ning ;

Wan, Ming ;

Wang, Ling ;

Hu, Jiong .

TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (08) :512e1-512e8

[32] Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: A single-center experience [J].

Chantepie, S. P. ;

Gac, A. C. ;

Reman, O. .

LEUKEMIA RESEARCH, 2014, 38 (05) :569-574

[33] Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML [J].

P Christopoulos ;

C Schmoor ;

M Waterhouse ;

R Marks ;

R Wäsch ;

H Bertz ;

J Finke .

Bone Marrow Transplantation, 2013, 48 :901-907

[34] Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis [J].

Robin, Marie ;

Porcher, Raphael ;

Wolschke, Christine ;

de Fontbrune, Flore Sicre ;

Alchalby, Haefaa ;

Christopeit, Maximilian ;

Cassinat, Bruno ;

Zabelina, Tatjana ;

de Latour, Regis Peffault ;

Ayuk, Francis ;

Socie, Gerard ;

Kroger, Nicolaus .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (07) :1206-1211

[35] Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies [J].

E P Alessandrino ;

P Bernasconi ;

A A Colombo ;

D Caldera ;

L Malcovati ;

D Troletti ;

L Vanelli ;

M Varettoni ;

F Montanari ;

M Lazzarino .

Bone Marrow Transplantation, 2004, 34 :1039-1045

[36] Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies [J].

Alessandrino, EP ;

Bernasconi, P ;

Colombo, AA ;

Caldera, D ;

Malcovati, L ;

Troletti, D ;

Vanelli, L ;

Varettoni, M ;

Montanari, F ;

Lazzarino, M .

BONE MARROW TRANSPLANTATION, 2004, 34 (12) :1039-1045

[37] A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation [J].

Gruellich, C. ;

Bertz, H. ;

Spyridonidis, A. ;

Mueller, Ci ;

Finke, J. .

BONE MARROW TRANSPLANTATION, 2008, 41 (10) :845-850

[38] A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation [J].

C Grüllich ;

H Bertz ;

A Spyridonidis ;

C I Müller ;

J Finke .

Bone Marrow Transplantation, 2008, 41 :845-850

[39] Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies [J].

Dominik Schneidawind ;

Birgit Federmann ;

Corina Buechele ;

Andrea Helwig ;

Jörg Schmohl ;

Wichard Vogel ;

Christoph Faul ;

Lothar Kanz ;

Wolfgang A. Bethge .

Annals of Hematology, 2016, 95 :115-124

[40] Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies [J].

Schneidawind, Dominik ;

Federmann, Birgit ;

Buechele, Corina ;

Helwig, Andrea ;

Schmohl, Joerg ;

Vogel, Wichard ;

Faul, Christoph ;

Kanz, Lothar ;

Bethge, Wolfgang A. .

ANNALS OF HEMATOLOGY, 2016, 95 (01) :115-124

← 1 2 3 4 5 →